These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21474967)

  • 1. Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
    Asahina H; Oizumi S; Inoue A; Kinoshita I; Ishida T; Fujita Y; Sukoh N; Harada M; Maemondo M; Saijo Y; Dosaka-Akita H; Isobe H; Nukiwa T; Nishimura M;
    Oncology; 2010; 79(5-6):423-9. PubMed ID: 21474967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
    Koizumi T; Agatsuma T; Ikegami K; Suzuki T; Kobayashi T; Kanda S; Yoshikawa S; Kubo K; Shiina T; Takasuna K; Matsuo A; Hayasaka M; Morikawa M; Ameshima S
    Clin Lung Cancer; 2012 Nov; 13(6):458-63. PubMed ID: 22402083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
    Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
    Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
    Yokouchi H; Yamazaki K; Kinoshita I; Konishi J; Asahina H; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M
    BMC Cancer; 2007 Mar; 7():51. PubMed ID: 17374153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
    Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
    Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
    Oh IJ; Ban HJ; Kim KS; Kim YC
    Lung Cancer; 2012 Jul; 77(1):121-7. PubMed ID: 22333554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
    Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
    Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
    Cella D; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Heyes A; Ochs JS; Wolf MK; Kay AC; Kris MG; Natale RB
    J Clin Oncol; 2005 May; 23(13):2946-54. PubMed ID: 15699477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
    Lie CH; Chang HC; Chao TY; Chung YH; Wang JL; Wang CC; Lin MC
    Clin Lung Cancer; 2011 Mar; 12(2):116-24. PubMed ID: 21550558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
    Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
    BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.
    Chen X; Li W; Hu X; Geng Y; Wang R; Yin Y; Shu Y
    Biomed Pharmacother; 2011 Dec; 65(8):542-6. PubMed ID: 21840160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
    Cho BC; Im CK; Park MS; Kim SK; Chang J; Park JP; Choi HJ; Kim YJ; Shin SJ; Sohn JH; Kim H; Kim JH
    J Clin Oncol; 2007 Jun; 25(18):2528-33. PubMed ID: 17577030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.
    Crinò L; Cappuzzo F; Zatloukal P; Reck M; Pesek M; Thompson JC; Ford HE; Hirsch FR; Varella-Garcia M; Ghiorghiu S; Duffield EL; Armour AA; Speake G; Cullen M
    J Clin Oncol; 2008 Sep; 26(26):4253-60. PubMed ID: 18779612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
    Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
    Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
    Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
    Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
    Stinchcombe TE; Socinski MA
    Oncologist; 2008 Sep; 13(9):933-44. PubMed ID: 18784157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.